香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不會 就因本公佈全部或任何部分內容而產生或因依賴該等內容而引致之任何 損失承擔任何責任。 Kiu Hung International Holdings Limited 僑 雄 國 際 控 股 有 限 公 司 （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：00381） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 全 年 業 績 公 佈 ...

Financial Performance - The group recorded a revenue of approximately HKD 193.9 million for the six months ended June 30, 2022, representing an increase of about 125% compared to HKD 86.3 million in the same period last year[5]. - The loss attributable to equity holders of the company was approximately HKD 23.5 million, a decrease from HKD 46.1 million in the previous year, primarily due to increased revenue from toys, gifts, and traditional Chinese medicine[5]. - Revenue for the six months ended June 30, 2022, was HKD 193,988,000, a significant increase from HKD 86,334,000 in the same period of 2021, representing a growth of 124.5%[37]. - Gross profit for the same period was HKD 60,623,000, compared to HKD 23,970,000 in 2021, indicating a gross margin improvement[37]. - The net loss for the six months ended June 30, 2022, was HKD 13,983,000, a reduction from a net loss of HKD 44,673,000 in 2021, showing an improvement of 68.7%[39]. - The reported total profit for the six months ended June 30, 2022, was HKD 19,386,000, compared to a loss of HKD 959,000 for the same period in 2021[64]. - The company incurred a loss of approximately HKD 13,983,000 for the six months ended June 30, 2022, raising concerns about its ability to continue as a going concern[53]. Revenue Segments - The toys and gifts segment generated revenue of approximately HKD 137.1 million, with a gross profit margin of 31.3%, up from 27.8% in the previous year, attributed to reduced material costs[7]. - The revenue from the traditional Chinese medicine business was approximately HKD 56.9 million, significantly up from HKD 7.8 million in the previous year[17]. - Total revenue from external customers for the toys and gifts segment was HKD 137,112,000, representing a significant increase from HKD 78,504,000 in the same period of 2021[61]. Cash and Liquidity - The group’s cash and bank balances were approximately HKD 75.4 million as of June 30, 2022, down from HKD 201.1 million as of December 31, 2021[19]. - The company reported a net cash outflow from operating activities of HKD 138,649,000 for the six months ended June 30, 2022, compared to HKD 28,788,000 for the same period in 2021, indicating a significant increase in cash burn[50]. - The company’s current liabilities exceeded its current assets by approximately HKD 253,174,000 as of June 30, 2022, indicating liquidity challenges[53]. - The company is actively negotiating with financial institutions to secure additional financing and extend repayment terms with creditors[55]. - The company is considering fundraising activities, including rights issues and public offerings, to raise new capital[55]. Assets and Liabilities - The company's total assets decreased to HKD 903,812,000 as of June 30, 2022, down from HKD 956,439,000 at the end of 2021[42]. - The total liabilities decreased to HKD 636,081,000 from HKD 658,843,000, showing a reduction of 3.4%[44]. - The company's equity attributable to shareholders decreased to HKD 94,149,000 from HKD 135,127,000, a decline of 30.4%[44]. - Inventory levels increased significantly to HKD 101,858,000 from HKD 35,355,000 in the previous year, indicating a rise of 187.5%[42]. - The net trade receivables increased to HKD 73,443,000 as of June 30, 2022, compared to HKD 26,963,000 at the end of 2021, reflecting a growth of approximately 172.5%[73]. Capital Structure and Financing - The group’s borrowings were approximately HKD 120.5 million as of June 30, 2022, compared to HKD 118.5 million as of December 31, 2021[19]. - The capital debt ratio as of June 30, 2022, was 264.8%, up from 180.9% as of December 31, 2021[20]. - The company completed a capital restructuring on June 27, 2022, consolidating every five existing shares into one new share with a par value of HKD 0.05[79]. - The company received valid acceptances for the issuance of 15,898,476 new shares under a rights issue on July 22, 2022, with 675,217,317 shares successfully placed at HKD 0.205 each[90]. - The total amount raised from the rights issue is approximately HKD 141,680,000, with a net amount of approximately HKD 139,810,000 after deducting all related expenses[91]. Operational Challenges - The group is evaluating the impact of the COVID-19 pandemic on its operations and financials, particularly regarding the delayed construction of high-end hotel casinos and residential properties[11]. - The company has implemented strict credit monitoring to minimize credit risk, with overdue balances reviewed regularly by senior management[73]. - The company has no significant legal claims or disputes pending as of the report date[87][88]. Dividends and Share Options - The group has decided not to declare any interim dividend for the period, consistent with the previous year[5]. - The company has no unexercised share options as of June 30, 2022, and the share option plan approved in May 2013 will expire on May 30, 2023[24].

Financial Performance - The company reported a revenue of approximately HKD 323.7 million for the fiscal year ending December 31, 2021, representing a 59.19% increase compared to HKD 203.4 million in 2020[4]. - The gross profit for the year was HKD 91.9 million, up 39.74% from HKD 65.8 million in the previous year[4]. - The loss attributable to shareholders was approximately HKD 226.8 million, a significant increase of 215.92% from HKD 71.8 million in 2020[4]. - The basic loss per share for the year was HKD 22.76, compared to HKD 13.48 in 2020, marking a 68.84% increase[4]. - The group reported a profit of approximately HKD 4,600,000 for the year, compared to a loss of HKD 5,600,000 in 2020[18]. - The group incurred a loss of approximately HKD 60,000,000 for the year, an increase from a loss of HKD 2,900,000 in 2020[19]. - The company reported a total comprehensive loss of HKD 209,930,000 for the year, compared to HKD 62,596,000 in 2020, highlighting ongoing challenges[167]. - The company reported a net loss of HKD 220,496,000 for 2021, compared to a net loss of HKD 70,102,000 in 2020, indicating a significant increase in losses[165]. Revenue Sources - The company’s toy and gift business generated revenue of approximately HKD 264.3 million, a 37.5% increase from HKD 192.3 million in 2020[15]. - The herbal medicine business generated revenue of approximately HKD 59,400,000, compared to zero in 2020[24]. - Revenue from North America was approximately HKD 264,000,000, up from HKD 190,000,000 in the previous year, accounting for 81.6% of total revenue[26]. Assets and Liabilities - The total assets of the company increased by 12.14% to HKD 956.4 million from HKD 852.9 million in the previous year[4]. - The company’s cash and cash equivalents increased to HKD 201,113,000 in 2021 from HKD 21,645,000 in 2020, indicating improved liquidity[169]. - The company reported a loss of approximately HKD 220,496,000 for the year ended December 31, 2021, with current liabilities totaling about HKD 258,444,000[178]. - The company’s net asset value decreased from HKD 293,991 thousand in 2020 to HKD 212,194 thousand in 2021, indicating a decline of approximately 27.8%[172]. Financial Strategy and Fundraising - The company plans to explore profitable investment opportunities and diversify its business and revenue base[9]. - The company plans to raise approximately HKD 141,000,000 through a rights issue at a subscription price of HKD 0.205 per share[179]. - The company is actively considering fundraising activities, including rights issues, public offerings, placements of new shares, and issuing convertible bonds[133]. - The group has established a clear organizational structure with defined responsibilities and authority for monitoring the performance of designated business units[137]. Corporate Governance - The board consists of three executive directors and six independent non-executive directors, ensuring independence and compliance with listing rules[111]. - The company has adopted a board diversity policy to enhance performance quality and ensure a balance of skills and experience among board members[120]. - The company has confirmed that public shareholding is sufficient, exceeding 25% of the total issued shares as of the report date[92]. - The company has received annual confirmations of independence from all independent non-executive directors, affirming their independence[94]. Risk Management - The group has adopted a risk management framework that includes identifying significant risks, assessing their impact, and implementing necessary measures to manage those risks[136]. - The board believes that the existing organizational structure and close supervision by management provide sufficient risk management and internal control[140]. - The board will regularly review the need for an internal audit function or engage independent professional service providers to assess the internal control and risk management systems[135]. Employee and Operational Insights - The workforce increased to 386 employees as of December 31, 2021, up from 356 employees in the previous year, indicating growth in operational capacity[48]. - The group’s total administrative expenses increased by approximately 9.2% to about HKD 78,500,000, primarily due to the acquisition of the herbal medicine business[28]. - The company has implemented effective paper usage measures to reduce its carbon footprint, including double-sided printing and recycling initiatives[97]. Investment Activities - The company completed the acquisition of a 51% stake in Hubei Jincao Tang Pharmaceutical Co., Ltd. for HKD 170 million, which will be paid through the issuance of convertible bonds[37]. - The acquisition of Hubei Jincao Tang Pharmaceutical Co. was completed, constituting a business combination, with fair value measurement of identifiable assets and liabilities required[150]. - Investment in associates as of December 31, 2021, includes approximately HKD 155,119,000 in Zhongle Development Co., HKD 132,334,000 in Anhui Fulao Wine Industry Development Co., and HKD 63,355,000 in USO Management & Holding Co. Ltd[148]. Auditor and Compliance - The auditor of the company has remained unchanged for the past three years, with the appointment confirmed at the annual general meeting[106]. - The company has complied with all applicable corporate governance code provisions, except for the deviation from code provision A.6.7 regarding independent non-executive directors' attendance at the annual general meeting[108]. - The audit committee held two meetings during the year, with all members being independent non-executive directors[131].

於開曼群島註冊成立之有限公司 股份代號 邁步向前 Leading the Way Towards | | | | 公司資料 | 2 | | --- | --- | | 財務概要 | 3 | | 主席報告書 | 4 | | 管理層討論及分析 | 6 | | 董事及高層管理人員簡介 | 13 | | 董事會報告 | 15 | | 企業管治報告 | 23 | | 獨立核數師報告 | 30 | | 經審核綜合財務報表 | | | 綜合損益表 | 36 | | 綜合損益及其他全面收入表 | 37 | | 綜合財務狀況表 | 38 | | 綜合權益變動表 | 40 | | 綜合現金流量表 | 41 | | 綜合財務報表附註 | 43 | | 五年財務概要 | 136 | 公司 資料 執行董事： 張啟軍先生 （主席） 陳劍先生 劉明卿先生 獨立非執行董事： 王小寧先生 鄭皓安先生 江俊榮先生 黎子彥先生 陳雨鑫女士 註冊辦事處 Zuill Corporate Services (Bermuda) Limited Continental Buildings 25 Church Street Hamilton HM 12 Be ...